Relapsed/Refractory Multiple Myeloma: Targeted Therapy and BCMA

Sagar Lonial, MD, FACP, explains the various ways to target and treat relapsed/refractory multiple myeloma, specifically focusing on BCMA and belantamab mafoditin as therapeutic agents.

EP. 1: Treatment Goals and Options for RRMM

May 3rd 2021

A multiple myeloma expert introduces and defines relapsed/refractory myeloma and discusses typical treatment strategies.

EP. 2: Considerations for Selecting Therapy in RRMM

May 3rd 2021

Sagar Lonial, MD, FACP, reviews targeted therapy options, and how they differ from other therapeutic approaches for relapsed/refractory myeloma.

EP. 3: BCMA as a Therapeutic Target for RRMM

May 3rd 2021

Dr Sagar Lonial, MD, FACP, comments on BCMA as a potential therapeutic target for multiple myeloma.

EP. 4: The DREAMM-2 Trial

May 3rd 2021

A leading myeloma expert reviews important data that led to the approval of belantamab mafodotin for heavily pretreated patients with relapsed/refractory multiple myeloma.

EP. 5: BCMA-Targeted Therapies for NDMM

May 3rd 2021

Sagar Lonial, MD, FACP, provides insight on the potential role of BCMA-targeted therapies for newly diagnosed patients with multiple myeloma.

EP. 6: Future Directions in MM Therapeutics

May 3rd 2021

Dr Sagar Lonial, MD, FACP, shares his thoughts on the future of targeted therapies for patients with multiple myeloma.